Treatment of severe XXXX : entering the era of targeted therapy.

@entity1 @entity32 @entity225 @entity4047 @entity565
INTRODUCTION: It is estimated that 5 - 10% of @entity565 @entity1 suffer from severe @entity565 . Severe @entity565 is associated with increased morbidity and mortality. These @entity1 are not controlled with currently available treatments and therefore additional treatment options are needed. Asthma is a heterogeneous disease, and different @entity565 @entity1 groups probably have different underlying pathophysiology. Novel therapies with, for example, monoclonal antibodies that target certain immunological pathways have become available. These novel treatments are not effective in all @entity1 but only in certain phenotypes. Areas covered: This review covers the current evidence and novel developments in treatment with monoclonal antibodies in different @entity565 phenotypes. This includes monoclonal antibodies against IgE, against @entity225 and antibodies targeting @entity4047 pathways. Although there is a certain overlap between @entity1 groups benefiting from these treatments, a more detailed identification of responder profiles for these therapies is needed for personalized therapy. Expert opinion: In recent years, novel monoclonal antibodies have been developed, which are a promising addition to existing therapy in the treatment of severe @entity565 with @entity32 and Th2-driven disease. We expect that several of the new antibodies will become available for clinical practice. In addition, it must be acknowledged that so far no effective strategies are available for @entity1 with non-eosinophilic @entity565 and further research and development is necessary for this @entity1 group.
